speciality-medicines-ltd

Incorporated in 2021 and based in Ahmedabad, Speciality Medicines Ltd is a pharmaceutical company focused on the marketing and distribution of high-value finished formulations used to treat complex, chronic, and rare conditions.

Business Verticals

• Super-Specialty Focus: Specializes in therapeutic areas such as Oncology (Cancer), Immunology, Neurology, Nephrology, and HIV/AIDS.

• Dual Operating Model: * Contract Manufacturing: Gets approved formulations manufactured via WHO-GMP certified third parties for international distribution.

  • Trading & Distribution: Sources registered pharmaceutical brands from manufacturers and distributes them across a pan-India network.

• Global Footprint: Exports to over 35 countries across Asia, Africa, and Europe, with 7 products already registered overseas and 54 more in the pipeline.

Track Record

• Rapid Revenue Growth: Revenue more than doubled from ₹27.52 Cr (FY24) to ₹58.27 Cr (FY25).

• Profitability: Net profit (PAT) grew nearly 3x from ₹2.93 Cr (FY24) to ₹8.61 Cr (FY25).

• Return Ratios: Reported a strong Return on Equity (ROE) of 37.85% and a Return on Net Worth (RoNW) of 28.30% for FY25.

• Product Range: Currently manages a portfolio of 128 products with plans to expand to 281 in the near future.

Speciality Medicines Ltd IPO GMP

As of March 20, 2026, the Grey Market Premium (GMP) is ₹0.

Note: The current GMP suggests a flat listing at the issue price of ₹124. However, early subscription data shows the NII (HNI) category is already seeing interest (1.60x), which may influence the premium in the coming days.

Speciality Medicines Ltd IPO Allotment Status

The allotment is scheduled to be finalized on March 25, 2026.

Check Speciality Medicines Allotment Status To check your status online, visit: [Check Allotment Status Here]

You can verify your status via:

• Registrar's website (Skyline Financial Services Pvt Ltd)

• BSE official portal

• Using your PAN number or Application ID

Strengths

• Niche Therapeutic Focus: Concentrating on high-cost, high-demand areas like oncology and rare diseases provides higher margins and stickier demand.

• Global Reach: Diversified revenue base with exports to 35+ countries mitigates the risk of relying solely on the Indian market.

• Asset-Light Model: By using contract manufacturing, the company maintains low capital expenditure and high flexibility.

• Quality Standards: Sources exclusively from WHO-GMP certified facilities, ensuring compliance with international regulatory standards.

Weakness

• Short Operating History: Incorporated only in 2021, the company has a limited track record for investors to judge long-term stability.

• Third-Party Dependency: Lacks in-house manufacturing, making it vulnerable to supply chain disruptions or quality issues at partner facilities.

• Legal Risks: There are ongoing legal proceedings involving a promoter which could pose potential reputational or governance risks.

• Intense Competition: Faces pricing pressure from much larger pharmaceutical giants and the rising adoption of low-cost biosimilars.

How the Company Will Use IPO Money

The fresh issue proceeds (₹29.14 Cr) will be utilized for:

• R&D Centre: ₹12.68 crores to establish a new Research & Development facility in Gujarat.

• Working Capital: ₹8.00 crores to meet incremental operational requirements.

• International Expansion: ₹2.99 crores for product registration and development in global markets.

• Marketing: ₹1.66 crores for brand promotion and participating in international industry events.

Lead Manager & Registrar

• Lead Manager: Unistone Capital Pvt. Ltd.

• Registrar: Skyline Financial Services Pvt Ltd Phone: +91 22 2851 1022 Email: ipo@skylinerta.com